Search

Dr. Gregory German of Unity Health Toronto will lead P-PEAKS UTI, an international clinical trial in which about 220 women with E. coli urinary tract infections lasting a year or more will receive either personalized phage therapy or placeb

The REPhRAME project, coordinated by Universitätsmedizin Frankfurt under Prof. Maria J.G.T. Vehreschild, has been awarded €15 million through Horizon Europe; it began in June 2026 and is planned to run for five years. It will assess in a ra

Non-peer-reviewed scoping-review poster from the NSU KPCOM Student Research Day (May 15, 2026), published on Cureus, that searched six databases for studies of bacteriophage therapy in autoimmune disease. It reports disease-associated chang

Precise Health SA, a Biopôle-based EPFL spin-out, has kicked off an Innosuisse Innovation Project worth approximately CHF 900,000 with the University of Geneva and Geneva University Hospitals (HUG). The project builds on its AI-powered Phag

PHAGE4DAIR, a Horizon Europe project coordinated by Qeen Biotechnologies (Canada), runs from 1 June 2026 to 31 May 2031 with an EU contribution of €14,869,038.73. It is a multicenter, randomized, double-blind, placebo-controlled, adaptive P

A Nature Communications Perspective by Aleksandra Petrović-Fabijan and Stephen T. Abedon argues that phage therapy must move beyond anecdote to clinical reproducibility, and identifies three foundational pillars to be addressed through inte

Tristan Ferry discusses PHAGEinLYON’s clinical experience with compassionate use and clinical trials in a talk hosted on Canal-U. Phages.fr on Canal-U

The fourth Japanese Phage Young Researchers’ Meeting was announced as a two-night residential gathering at the University Seminar House in Hachioji, July 29–31, 2026, for students and researchers within five years of completing a doctoral d

The University at Buffalo reports clearance of a patient’s chronic MRSA infection following phage therapy alongside antibiotics and hip hardware replacement. Patrick Kenney’s team developed the patient-specific phage after years of recurren

Terlizzi and colleagues report a systematic review in the International Journal of Infectious Diseases of phage therapy in cystic fibrosis: 19 studies covering 51 patients and 52 phage treatment courses, mostly against Pseudomonas aeruginos

An ODIN-funded collaborative project led by Professor Hanne Ingmer (University of Copenhagen) brings academic and industry partners together to develop next-generation tools for phage-based therapies against chronic wound and urinary tract

Contagion Live article by Amer El-Ghali and Dana Holger reviewing phage-antibiotic combinations (PACs) in refractory multidrug-resistant infections: preclinical synergy is consistent and compassionate-use reports show safety and frequent cl

Final results of the randomized, placebo-controlled, double-blind Phase 1 trial of oral SNIPR001 in healthy volunteers were published in The Lancet Microbe. The trial evaluated safety and tolerability after twice-daily dosing for seven days

Unity Health Toronto profiles Gregory German and Steffanie Strathdee’s work on phage therapy. German has treated patients and led a Canadian-first trial for chronic infections; Strathdee helped assemble the cross-border team that treated he

A Bioengineering & Translational Medicine study from the University of Sydney spray-dried phage PEV1 with polyvinylpyrrolidone (PVP) grades K15 to K100 and stored it for 180 days at 4, 22 and 40 °C and 15 to 53% relative humidity. At 33% re

An automated screening platform combining liquid-handling robotics, standardized phenotypic assays and computer-vision enumeration screens large phage collections against clinical bacterial strain panels and has assessed more than 3.8 milli

Tristan Ferry, professor of infectious diseases and coordinator of the Reference Center for Complex Osteoarticular Infections (Crioac) at Hospices Civils de Lyon, explains how phage therapy works, its advantages (specificity, self-amplifica

Armata Pharmaceuticals announced on January 13, 2026 an FDA End-of-Phase 2 written response confirming that safety and efficacy data from its Phase 2a diSArm study support advancing AP-SA02, an intravenous S. aureus bacteriophage cocktail,

A $3.3 million NIAID contract supports a proof-of-concept clinical trial of LBP-PA01 for pneumonia, with further funding conditional on milestones. www.locus-bio.com

PHTRP lists a patient-perspective panel discussion on experiences with phage therapy. Phage Hunters Training and Research Program